Australia New Zealand Gynaecological Oncology Group
3 clinical trials · Sponsor
◉ Watch Australia New Zealand Gynaecological Oncology Group
| Record | Firm | Date |
|---|---|---|
| Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy (NCT05614453) | Australia New Zealand Gynaecological Oncology Group | 2023-06-01 |
| EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (NCT05619913) | Australia New Zealand Gynaecological Oncology Group | 2023-05-22 |
| Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (NCT03933761) | Australia New Zealand Gynaecological Oncology Group | 2019-07-29 |
Track Australia New Zealand Gynaecological Oncology Group automatically
Every clearance here is in the API, with alerts when new ones post.